JP2019535267A - Ｇｄｎｆ融合ポリペプチド及びその使用方法 - Google Patents

Ｇｄｎｆ融合ポリペプチド及びその使用方法 Download PDF

Info

Publication number
JP2019535267A
JP2019535267A JP2019525814A JP2019525814A JP2019535267A JP 2019535267 A JP2019535267 A JP 2019535267A JP 2019525814 A JP2019525814 A JP 2019525814A JP 2019525814 A JP2019525814 A JP 2019525814A JP 2019535267 A JP2019535267 A JP 2019535267A
Authority
JP
Japan
Prior art keywords
gdnf
fusion polypeptide
sequence
gdnf fusion
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019525814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535267A5 (enExample
Inventor
エス． シーラ、ジャスバー
エス． シーラ、ジャスバー
ラシェイ、ジェニファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keros Therapeutics Inc
Original Assignee
Keros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keros Therapeutics Inc filed Critical Keros Therapeutics Inc
Publication of JP2019535267A publication Critical patent/JP2019535267A/ja
Publication of JP2019535267A5 publication Critical patent/JP2019535267A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019525814A 2016-11-10 2017-11-09 Ｇｄｎｆ融合ポリペプチド及びその使用方法 Pending JP2019535267A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662420480P 2016-11-10 2016-11-10
US62/420,480 2016-11-10
PCT/US2017/060953 WO2018089702A1 (en) 2016-11-10 2017-11-09 Gdnf fusion polypeptides and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2019535267A true JP2019535267A (ja) 2019-12-12
JP2019535267A5 JP2019535267A5 (enExample) 2020-12-24

Family

ID=62110755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019525814A Pending JP2019535267A (ja) 2016-11-10 2017-11-09 Ｇｄｎｆ融合ポリペプチド及びその使用方法

Country Status (13)

Country Link
US (3) US11912750B2 (enExample)
EP (2) EP3538560B1 (enExample)
JP (1) JP2019535267A (enExample)
CN (1) CN110461880A (enExample)
AU (2) AU2017357931B2 (enExample)
CA (1) CA3043179A1 (enExample)
DK (1) DK3538560T3 (enExample)
ES (1) ES3071925T3 (enExample)
FI (1) FI3538560T3 (enExample)
HR (1) HRP20260618T1 (enExample)
LT (1) LT3538560T (enExample)
PT (1) PT3538560T (enExample)
WO (1) WO2018089702A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529497A (ja) * 2020-06-14 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 補体因子ｉ関連組成物および方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
CA3043184A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
BR112021024636A2 (pt) * 2019-06-10 2022-01-18 Infectious Disease Res Inst Métodos e composições de replicons de astrovírus
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
CN113046381A (zh) * 2021-04-12 2021-06-29 南华大学 用于分离生物体内特异性蛋白-dna复合体的方法、融合蛋白及其制备方法
CN115927288A (zh) * 2022-07-28 2023-04-07 南京林业大学 一种固定化脂肪tll酶及固体结合肽在其固定化中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2781459B2 (ja) * 1989-04-29 1998-07-30 デルタ バイオテクノロジー リミテッド ヒト血清アルブミンのｎ―末端フラグメント含有融合蛋白質
JP2007289200A (ja) * 1999-12-24 2007-11-08 Genentech Inc 生理活性化合物の消失半減期延長のための方法及び組成物
JP2009504164A (ja) * 2005-08-12 2009-02-05 アムジエン・インコーポレーテツド 修飾されたＦｃ分子
JP2012529272A (ja) * 2009-06-11 2012-11-22 アンジオケム インコーポレーテッド Ｇｄｎｆおよびｂｄｎｆを中枢神経系へ送達するための融合タンパク質
WO2015143199A1 (en) * 2014-03-20 2015-09-24 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20040175795A1 (en) 1991-09-20 2004-09-09 Amgen Inc. Glial derived neurotrophic factor
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
US5733875A (en) 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996033731A1 (en) 1995-04-26 1996-10-31 Regeneron Pharmaceuticals, Inc. Methods of using neurotrophic factors to enhance neuronal grafts
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
AU1121997A (en) 1995-11-29 1997-06-19 Amgen, Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5837681A (en) 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US6455277B1 (en) 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
JP2002505576A (ja) 1997-05-30 2002-02-19 アムジエン・インコーポレーテツド 神経栄養因子レセプター
WO2000034475A2 (en) 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003256613A1 (en) 2002-07-19 2004-02-09 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
AU2007285763B2 (en) * 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
CN101687933B (zh) * 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
EP2152751A1 (en) * 2007-05-31 2010-02-17 Genmab A/S Fusion or linked proteins with extended half life
WO2009070597A2 (en) * 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2015073727A1 (en) * 2013-11-13 2015-05-21 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2781459B2 (ja) * 1989-04-29 1998-07-30 デルタ バイオテクノロジー リミテッド ヒト血清アルブミンのｎ―末端フラグメント含有融合蛋白質
JP2007289200A (ja) * 1999-12-24 2007-11-08 Genentech Inc 生理活性化合物の消失半減期延長のための方法及び組成物
JP2009504164A (ja) * 2005-08-12 2009-02-05 アムジエン・インコーポレーテツド 修飾されたＦｃ分子
JP2012529272A (ja) * 2009-06-11 2012-11-22 アンジオケム インコーポレーテッド Ｇｄｎｆおよびｂｄｎｆを中枢神経系へ送達するための融合タンパク質
WO2015143199A1 (en) * 2014-03-20 2015-09-24 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOL. BIOENG., 2008, 100(2), PP.387-396, JPN6021032948, ISSN: 0004737136 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529497A (ja) * 2020-06-14 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 補体因子ｉ関連組成物および方法

Also Published As

Publication number Publication date
CN110461880A (zh) 2019-11-15
LT3538560T (lt) 2026-07-10
EP3538560B1 (en) 2026-04-08
DK3538560T3 (da) 2026-07-13
US20190284251A1 (en) 2019-09-19
PT3538560T (pt) 2026-06-15
NZ754163A (en) 2026-01-30
US20260022150A1 (en) 2026-01-22
FI3538560T3 (fi) 2026-07-03
HRP20260618T1 (hr) 2026-07-17
WO2018089702A1 (en) 2018-05-17
EP3538560A1 (en) 2019-09-18
US12404313B2 (en) 2025-09-02
US20240209048A1 (en) 2024-06-27
US11912750B2 (en) 2024-02-27
ES3071925T3 (en) 2026-06-26
AU2025201554A1 (en) 2025-03-27
AU2017357931A1 (en) 2019-06-20
CA3043179A1 (en) 2018-05-17
EP4782462A2 (en) 2026-07-29
EP3538560A4 (en) 2020-06-17
AU2017357931B2 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
US12404313B2 (en) GDNF fusion polypeptides and methods of use thereof
JP7625672B2 (ja) アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
US10610568B2 (en) Compositions and methods of use for treating metabolic disorders
US10323075B2 (en) Compositions and methods of use for treating metabolic disorders
CN104995206B (zh) 新颖的胰岛素类似物及其用途
JP2022118184A (ja) コンジュゲートされたｃ１エステラーゼインヒビター及びその使用
CN113396158A (zh) Lpl-gpihbp1融合多肽
HK40015865A (en) Gdnf fusion polypeptides and methods of use thereof
HK40015852B (en) Activin receptor type iia variants and methods of use thereof
WO2014014816A2 (en) Methods of treating glucose metabolism disorders
CA2961587A1 (en) Compositions and methods of use for treating metabolic disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220329